Aurora Cannabis Announces CFO Transition, Completion of Share Consolidation

EDMONTON, Alberta, Feb. 20, 2024 – PRESS RELEASE – Aurora Cannabis Inc., the Canadian based leading global medical cannabis company, announced that Simona King, a former executive of Bristol Myers-Squibb, a leading multinational pharmaceutical company, has been appointed as chief financial officer (CFO) of the company, effective Feb. 21, 2024.

King brings more than 25 years of progressive finance leadership experience, with deep business knowledge and proven success with global and emerging organizations. She served nearly 20 years with Bristol Myers-Squibb, where she held increasingly senior finance roles and enabled the company's growth strategy. 

Glen Ibbott, current CFO, will be stepping down from his full-time role effective Feb. 20 to pursue new opportunities. He will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to King.

CFO Transition

"As our company continues to evolve, we are thrilled to welcome Simona King to Aurora,” CEO Miguel Martin said. “Simona has spent her career growing businesses, improving operational efficiencies, and leading a best-in-class global financial organization. Her deep operational and financial knowledge, combined with her extensive experience across many corporate functions and deep commitment to developing talent, make her uniquely positioned to help lead Aurora into its next phase of growth."

Martin added, "On behalf of our board of directors, and the entire Aurora team, I would like to offer our sincere thanks and appreciation to Glen. Since 2017, Glen has dedicated immeasurable time, energy and passion to shaping Aurora into a leading medical cannabis company; and we have been fortunate to have his leadership over the years as we navigated this emerging industry. We wish him all the best for his future endeavors."

King brings deep financial expertise across corporate, operations and international business units. In recent years, she has spread her professional reach, joining fast-moving public companies in emerging sectors, including biotech. She joins Aurora most recently as the CFO of a number of clinical stage biotechnology companies.

Share Consolidation

Aurora also announces the completion of its previously announced consolidation of the common shares of the company on a 10-to-1 basis. The common shares will begin trading on a post-consolidation basis on the Nasdaq capital market and the Toronto Stock Exchange under the symbol "ACB" at the opening of trading Feb. 20.